**Supplemental Table 4.** Correlations between 0-1 year changes (Δ) in serum CXCL14 levels and those in clinical, endocrine-metabolic, body composition, and abdominal fat partitioning variables in girls with Polycystic Ovary Syndrome  (PCOS, N=15) who received a low-dose combination of Spironolactone (50 mg/d), Pioglitazone (7.5 mg/d) and Metformin (850 mg/d) (SPIOMET) for 1 year.

| SPIOMET (N= 15) | | |
|---|---|---|
| | Δ CXCL14 (ng/ mL) | |
| | R | *P* |
| **Auxology** | | |
| Δ BMI (kg/m$^2$) | -0.108 | 0.702 |
| Δ BMI Z-score | -0.108 | 0.703 |
| **Endocrine-Metabolic variables** | | |
| Δ Testosterone (nmol/ L) | 0.293 | 0.331 |
| Δ SHBG (nmol/ L) | -0.144 | 0.608 |
| Δ FAI | 0.017 | 0.955 |
| Δ Glucose (mmol/ L) | 0.511 | 0.051 |
| Δ Fasting insulin (pmol/ L) | **0.588** | **0.021** |
| Δ HOMA-IR | **0.630** | **0.012** |
| Δ HDL-cholesterol (nmol/ L) | -0.198 | 0.498 |
| Δ LDL-cholesterol (nmol/ L) | -0.446 | 0.096 |
| Δ Triglycerides (nmol/ L) | -0.045 | 0.874 |
| Δ HMW adiponectin (mg/ L) | 0.037 | 0.903 |
| Δ usCRP (mg/ L) | -0.009 | 0.980 |
| **Body composition (DXA)** | | |
| Δ Bone mineral density (g/ cm$^2$) | -0.205 | 0.463 |
| Δ Lean mass (kg) | -0.176 | 0.531 |
| Δ Fat mass (kg) | -0.036 | 0.900 |
| Δ Abdominal fat (kg) | -0.243 | 0.384 |
| **Abdominal fat partitioning (MRI)** | | |
| Δ Subcutaneous fat (cm$^2$) | -0.111 | 0.693 |
| Δ Visceral fat (cm$^2$) | -0.187 | 0.504 |
| Δ Hepatic fat (%) | 0.226 | 0.417 |
| Δ Central (hepato-visceral) fat | -0.083 | 0.769 |

CXCL14, C-X-C motif chemokine ligand-14, BMI, body mass index; SHBG, sex hormone-binding globulin; FAI, free androgen index; HOMA-IR, homeostasis model assessment insulin resistance; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HMW, high molecular weight; usCRP, ultra-sensitive C-reactive protein; DXA, dual X-ray absorptiometry; MRI, magnetic resonance imaging.
Results are Pearson correlation coefficients and P values.